Colossal generates value not by selling resurrected animals but by spinning out valuable technology companies developed during its R&D, such as a computational biology platform. The long-term vision involves biodiversity credits rather than direct sales.
Colossal clarifies its process is not true cloning but "functional de-extinction." It involves editing the genome of a close living relative (like a gray wolf) to reintroduce the specific genes and traits of an extinct species, using the living animal as a 99%+ genetic base.
CEO Ben Lamb counters ethical criticism by arguing that humanity is already negatively "playing God" by causing mass extinction. He posits a moral obligation to use technology to reverse the damage we've caused, turning the common critique on its head.
Colossal's CEO admits that headline-grabbing projects like the dire wolf overshadow more impactful but less "sexy" work, such as saving the critically endangered red wolf. The glamorous projects act as a funnel for attention and funding for broader conservation efforts.
Facing immense ethical questions about technologies like artificial wombs, Colossal doesn't wait for regulation. It establishes its own clear, public guardrails—such as refusing to work on humans or primates and tying every project back to conserving an existing endangered species.
Colossal CEO Ben Lamb, a software entrepreneur with no biology background, approached top geneticist George Church seeking world-changing problems. His ability to build teams and secure capital, unconstrained by scientific dogma, was key to launching the ambitious de-extinction venture.
Colossal CEO Ben Lamb argues that the scientific community's debate over whether his creation is a "true" dire wolf is a semantic distraction. He contends this argument overshadows the unprecedented scientific milestone of creating live animals from 12,000-year-old DNA.